Literature DB >> 22635057

Assessing and managing metabolic syndrome and cardiovascular risk in midlife women.

Jessica Shank Coviello1, M Tish Knobf, Sarah Laclergue.   

Abstract

BACKGROUND: The components of metabolic syndrome (MetS), a major cardiovascular risk in women that includes diabetes, hypertension, and dyslipidemia, can evolve during the perimenopause transition. Lifestyle interventions have been shown to ameliorate or prevent individual components of MetS.
PURPOSE: This article will describe the hormonal and vascular changes occurring during perimenopause and discuss how they set the stage for MetS in women. The available screening tools (Framingham Assessment for Coronary Heart Disease vs Framingham General Cardiovascular Risk Profile vs Reynolds Risk Assessment) will be compared and contrasted within the context of the 2011 Updated Guidelines for the Prevention of Cardiovascular Disease in Women via case study. CONCLUSIONS AND CLINICAL IMPLICATIONS: Target goals and interventions to reduce or ameliorate the components of MetS will be presented, with a focus on achieving ideal cardiovascular health.

Entities:  

Mesh:

Year:  2013        PMID: 22635057     DOI: 10.1097/JCN.0b013e31823cbef8

Source DB:  PubMed          Journal:  J Cardiovasc Nurs        ISSN: 0889-4655            Impact factor:   2.083


  2 in total

1.  A randomised controlled trial of a physical activity and nutrition program targeting middle-aged adults at risk of metabolic syndrome in a disadvantaged rural community.

Authors:  Krysten Blackford; Jonine Jancey; Andy H Lee; Anthony P James; Peter Howat; Andrew P Hills; Annie Anderson
Journal:  BMC Public Health       Date:  2015-03-25       Impact factor: 3.295

2.  The Effects of Mobile-App-Based Low-Carbohydrate Dietary Guidance on Postprandial Hyperglycemia in Adults with Prediabetes.

Authors:  Xiaoyu Chen; Haihua Su; Daisuke Kunii; Kousuke Kudou; Yiyan Zhang; Ying Zhao; Dan Zhang; Yuanyuan Xing; Jiaqi Teng; Zhiqiang Nie; Xinxin Liu; Kaijun Niu; Yong Zhao; Qi Guo
Journal:  Diabetes Ther       Date:  2020-09-01       Impact factor: 2.945

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.